peptide-solutions
RETATRUTIDE
Triple-action GLP-1/GIP/Glucagon receptor agonist
Research Compound
Manufactured under strict quality control protocols with full analytical testing. Certificate of Analysis (COA) available upon request.
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Research highlights its potential for metabolic syndrome and obesity.
Compound Specifications
Scientific Documentation
Research Reference
Detailed research information, pharmacological profile, and handling specifications
Mechanism of Action
Retatrutide activates GLP-1R for appetite suppression and glycemic control, GIPR for enhanced insulin secretion and fat metabolism, and GcgR for increased energy expenditure — creating synergistic metabolic effects.
Research Use Only Disclaimer
This product is intended strictly for laboratory and research purposes only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm that you are an authorized researcher or institution and that this product will be used solely for legitimate research purposes in compliance with all applicable laws and regulations.
Related Compounds
Other research peptides you may be interested in
SEMAGLUTIDE
GLP-1 receptor agonist for metabolic research
from $78
TIRZEPATIDE
Dual GLP-1/GIP receptor agonist for metabolic research
from $104
TESAMORELIN 10MG
GHRH analog for metabolic and body composition research
$65